Antitumor agents 259. Design, syntheses, and structure-activity relationship study of desmosdumotin C analogs

Journal of Medicinal Chemistry

Volumn 50, Issue 14, 2007, Pages 3354-3358

  Nakagawa Goto, Kyoko ^a   Chen, Tzu Hsuan ^a   Peng, Chieh Yu ^a   Bastow, Kenneth F ^a   Wu, Jiu Hong ^b   Lee, Kuo Hsiung ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b 306 HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 HYDROXY 3 (NAPHTHALEN 1 YL)ALLYIDENE] 5 METHOXY 4,6,6 TRIMETHYLCYCLOHEX 4 ENE 1,3 DIONE; 2 METHYLDESMOSDUMOTIN C; 2,4,6 TRIMETHYLDESMOSDUMOTIN C; 2,6 DIMETHYLDESMOSDUMOTIN C; 3 VINYLDESMOSDUMOTIN C; 3',3' DIMETHYL 5' ETHYLDESMOSDUMOTIN C; 3',3',5' TRIETHYLDESMOSDUMOTIN C; 3',3',5' TRIPROPYLDESMOSDUMOTIN C; 3,5 DIMETHYLDESMOSDUMOTIN C; 4 BROMO 3',3',5' TRIPROPYLDESMOSDUMOTIN C; 4 ETHYLDESMOSDUMOTIN C; 4 FLUORODESMOSDUMOTIN C; 4 METHYL 3',3',5' TRIETHYLDESMOSDUMOTIN C; 4 METHYLDESMOSDUMOTIN C; ANTINEOPLASTIC AGENT; DESMOSDUMOTIN C DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BROMINATION; CANCER INHIBITION; CELL DIVISION; CYTOTOXICITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ALKENES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; FEMALE; KETONES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34447518998     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0702534     Document Type: Article

References (16)

1. Balunas, M. J.; Kinghorn, A. D. Drug discovery from medicinal plants. Life Sci. 2005, 78, 431-441.
2. Rollinger, J. M.; Langer, T.; Stuppner, H. Strategies for efficient lead structure discovery from natural products. Curr. Med. Chem. 2006, 13, 1491-1507.
3. Jones, W. P; Chin, Y. W.; Kinghorn, A. D. The role of pharmacognosy in modern medicine and pharmacy. Curr. Drug Targets 2006, 7, 247-264.
4. Butler, M. S. Natural products to drugs: Natural product derived compounds in clinical trials. Nat. Prod. Rep. 2005, 22, 162-195.
5. Koehn, F. E.; Carter, G. T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discovery 2005, 4, 206-220.
6. Paterson, I.; Anderson, E. A. The renaissance of natural products as drug candidates. Science 2005, 310, 451-453.
7. Tan, G.; Gyllenhaal, C.; Soejarto, D. D. Biodiversity as a source of anticancer drugs. Curr. Drug Targets 2006, 7, 265-277.
8. http://www.who.int/mediacentre/factsheets/fs297/en/.
9. Chung Yao Da Tzu Dien (Dictionary of Chinese Materia Medicia); Jiang Su New Medical College, Ed.; Shanghai Science & Technology Press: Hong Kong, 1977; Vol. 2, p 1919.
10. Wu, J. H.; McPhail, A. T.; Bastow, K. F.; Shiraki, H.; Ito, J.; Lee, K. H. Tetrahedron Lett. 2002, 43, 1391-1393.
11. Nakagawa-Goto, K.; Wu, J. H.; Lee, K. H. First total synthesis of desmosdumotin C. Syn. Commun. 2005, 35, 1735-1739.
12. Nakagawa-Goto, K.; Wu, J. H.; Bastow, K. F.; Wu, C. C.; Lee, K. H. Antitumor agents 243. Syntheses and cytotoxicity of desmosdumotin C derivatives. Bioorg. Med. Chem. 2005, 13, 2325-2330.
13. Bick, I. R. C.; Horn, D. H. D. Nuclear magnetic resonance studies. V. The tautomerism of tasmanone and related β-triketones. Aust. J. Chem. 1965, 18, 1405-1410.
14. (a) Wollenweber, E.; Dietz, V. H.; Schilling, G.; Favre-Bonvin, J.; Smith, D. M. Flavonoids from chemotypes of the goldback fern, Pityrogramma tiangularis. Phytochemistry 1985, 24, 965-972.
15. (b) Sbit, M.; Dupont, L.; Dideberg, O.; Vilain, C. Structure of ceroptene. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1987, C43, 2204-2206.
16. Nakanishi, Y.; Chang, F.-R.; Liaw, C.-C.; Wu, Y.-C.; Bastow, K. F.; Lee, K.-H. Acetogenins as selective inhibitors of the human ovarian 1A9 tumor cell line. J. Med. Chem. 2003, 46, 3185.